Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals

News provided by

Feb 21, 2012, 04:00 ET

STOCKHOLM, February 21, 2012 /PRNewswire/ --

Bactiguard has signed an exclusive co-operation with Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India. A signing process will take place at the Swedish Ambassador's residency tonight.

Cadila Pharmaceuticals will sell the entire line of Bactiguard´s products throughout India. The Indian medical device market is currently worth approximately 2 billion US dollar and growing 15% annually.

"For Bactiguard this is a milestone. India is one of the world's most interesting and fastest growing markets right now, and we are proud to be able to help India with our expertise in the field of infection protection. We are hoping to reduce the number of hospital acquired infections and thereby also reduce the use of antibiotics in India together with Cadila. I am very proud to be able to work with Cadila to improve health care in India", says Christian Kinch, CEO of Bactiguard.

Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals Ltd. has explained why Cadila has chosen to work with Bactiguard. "We have chosen to work with Bactiguard of Sweden because hospital- acquired infections are a big problem for patients in our country and Bactiguard has a unique solution targeted at preventing health care associated infections. We are confident that hospitals in our country will embrace Bactiguard's clinically proven solution in order to help save lives in India."

This co-operation between Cadila Pharmaceuticals and Bactiguard was facilitated by Dr.C.B. Sanjeevi of Karolinska Institute and Invest Sweden assisted together. Another important role was played by the Swedish EKN, Export Credit Guarantee Authority to make the exclusive agreement.

Photo text: Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals Ltd together with
Mr Christian Kinch, CEO, Bactiguard

Bactiguard provides world-leading solutions preventing hospital-acquired infections - the 4th largest cause of death in the western world. By using Bactiguard technology Governments can reduce healthcare cost, lower the use of antibiotics and save lives. The Bactiguard technology consists of an extremely thin noble metal coating, with antimicrobial and biocompatible properties that can be used on all sorts of medical devices. The Bactiguard coated urinary catheter has since 1995 been used by more than 110 million patients in the US. Today Bactiguard offers a full range portfolio within infection prevention in the urinary tract, respiratory tract and blood stream.

Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, it has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over 90 other countries across the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals.

http://www.bactiguard.com

SOURCE Bactiguard